May 27, 2020
After seeing lackluster uptakes initially, SGLT2 inhibitors have seen accelerating sales and now apparently make a 100 billion yen market in Japan on the back of new evidence on cardiovascular risk reductions, according to a Jiho estimate based on FY2019...read more